Ignite Creation Date:
2024-05-06 @ 2:15 PM
Last Modification Date:
2024-10-26 @ 1:27 PM
Study NCT ID:
NCT04262089
Status:
COMPLETED
Last Update Posted:
2023-12-05
First Post:
2020-01-28
Brief Title:
Neo-adjuvant Pembrolizumab in dMMR POLE-EDM Uterine Cancer Patients a Feasibility Study
Sponsor:
University Medical Center Groningen
Organization:
University Medical Center Groningen
Organization Data
Organization:
University Medical Center Groningen
Class:
OTHER
Study ID:
PAM-UMCG-001
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
University Medical Center Groningen
Lead Sponsor Class:
OTHER
Responsible Party:
Hans W Nijman MD PHD
Responsible Party Title:
Principal Investigator
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
University Medical Center Groningen
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Merck Sharp Dohme LLC | INDUSTRY |